

Resource Summary Report

Generated by [dkNET](#) on Aug 29, 2026

Phospho-YAP (Ser127) Antibody

RRID:AB_2218913

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4911, RRID:AB_2218913

Antibody Information

URL: http://antibodyregistry.org/AB_2218913

Proper Citation: Cell Signaling Technology Cat# 4911, RRID:AB_2218913

Target Antigen: Yap1

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W. Info: Used By NYUIHC-881.
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Phospho-YAP (Ser127) Antibody

Description: This polyclonal targets Yap1

Target Organism: mouse, human

Antibody ID: AB_2218913

Vendor: Cell Signaling Technology

Catalog Number: 4911

Record Creation Time: 20250820T033934+0000

Record Last Update: 20250820T165024+0000

Ratings and Alerts

- Independent validation by the NYU Langone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Phospho-YAP (Ser127) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 105 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Shaha SZ, et al. (2026) aPKC- γ III promotes trophoblast fusion by altering Par-3 interactions with Hippo signaling kinase LATS1. Stem cell reports, 21(7), 102975.

Potter R, et al. (2026) The serotonin receptor 2b (5-HT_{2B}) modulates heart remodeling following myocardial infarction via regulation of Hippo pathway. iScience, 29(2), 114825.

Fruzzetti F, et al. (2026) Improving Nonviral Gene Delivery by Activating Mechanosensing-Dependent Endocytic Pathways. ACS applied materials & interfaces.

Yu BM, et al. (2026) Yes-Associated Protein Drives Helicobacter pylori-Induced Metaplastic Changes in Gastric Epithelium. Cellular and molecular gastroenterology and hepatology, 20(9), 101814.

Xu X, et al. (2026) A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma. Cancer research, 86(15), 3666.

Zhang X, et al. (2026) HDAC inhibitors reverse YAP-driven immune resistance in NSCLC: mechanistic and translational evidence. Journal for immunotherapy of cancer, 14(6).

Xiao C, et al. (2025) Pharmacological targeting of large tumor suppressor kinases (LATS) 1 and 2 augments tissue repair and regeneration. British journal of pharmacology.

Li S, et al. (2025) Glutamine synthetase modulates YAP activation by stabilizing LATS under glutamine homeostasis. Cell reports, 44(12), 116620.

Männistö A, et al. (2025) Combined angiogenic and hypertrophic gene therapy enhances skeletal muscle growth. American journal of physiology. Cell physiology, 329(2), C540.

Cao X, et al. (2025) RIPK4 promotes epidermal differentiation through phase separation and activation of LATS1/2. Developmental cell.

Killarney ST, et al. (2025) PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State. *Cancer discovery*, 15(3), 595.

Huang X, et al. (2025) The Hippo pathway kinase MST1 mediates a feedback loop to maintain NLRP3 inflammasome homeostasis. *Cell reports*, 44(8), 116076.

Dimari G, et al. (2025) Mesenchymal-epithelial transition reduces proliferation but increases immune evasion in tumor spheroids. *iScience*, 28(8), 113023.

Stanland LJ, et al. (2025) A first-in-class EGFR-directed KRAS G12V selective inhibitor. *Cancer cell*.

Warren R, et al. (2024) Cell competition drives bronchiolization and pulmonary fibrosis. *Nature communications*, 15(1), 10624.

Rao K, et al. (2024) Myoglobin modulates the Hippo pathway to promote cardiomyocyte differentiation. *iScience*, 27(3), 109146.

Peng L, et al. (2024) Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity. *Cell reports*, 43(4), 114003.

Huang M, et al. (2024) ALK upregulates POSTN and WNT signaling to drive neuroblastoma. *Cell reports*, 43(3), 113927.

Yu Lin MO, et al. (2024) YAP/TAZ Drive Agrin-Matrix Metalloproteinase 12-Mediated Diabetic Skin Wound Healing. *The Journal of investigative dermatology*.

Xu CY, et al. (2024) Angiotensin II type-2 receptor signaling facilitates liver injury repair and regeneration via inactivation of Hippo pathway. *Acta pharmacologica Sinica*.